Comparative Pharmacology
Head-to-head clinical analysis: DETROL LA versus HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL LA versus HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE.
DETROL LA vs HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tolterodine is a competitive muscarinic receptor antagonist. It blocks acetylcholine binding at muscarinic receptors (M1–M5), reducing detrusor muscle contraction and bladder pressure, thereby increasing bladder capacity and decreasing urinary frequency.
Hydrocodone is a mu-opioid receptor agonist; homatropine methylbromide is an anticholinergic that reduces gastrointestinal motility and secretions.
4 mg orally once daily; may be reduced to 2 mg once daily based on tolerability.
1 tablet (containing homatropine methylbromide 5 mg and hydrocodone bitartrate 5 mg) orally every 4 to 6 hours as needed for cough. Maximum 6 tablets per 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5-10 hours) for the extended-release formulation, allowing once-daily dosing.
Hydrocodone: Terminal elimination half-life 3.8-6.4 hours (mean ~4.5 h) in adults; prolonged in hepatic/renal impairment (up to 12-15 h). Homatropine methylbromide: Terminal half-life ~4-6 hours via quaternary structure limiting CNS penetration.
Approximately 77% eliminated in urine (primarily as metabolites, <1% unchanged) and 17% in feces.
Hydrocodone: Renal excretion of metabolites (hydromorphone, norhydrocodone) as glucuronide conjugates (~60%) and unchanged drug (<10%). Biliary/fecal elimination accounts for ~20-30%. Homatropine methylbromide: Predominantly fecal elimination via biliary excretion as unchanged quaternary ammonium compound (~70-80%); renal excretion of unchanged drug (~10-20%).
Category C
Category D/X
Anticholinergic
Anticholinergic